Dasatinib + Quercetin: The First Clinically Proven Senolytic Combination

Expert Summary

The D+Q protocol stands as the single most evidence-backed senolytic intervention in human medicine. The Xu et al. (2018) Nature Medicine paper demonstrated: measurable reduction in p16+p21-positive senescent cells in adipose tissue biopsies, reduction in circulating SASP factors (IL-6, MMP-3, MMP-9), and improvement in physical function (walking speed, chair stand, stair climbing) in patients with idiopathic pulmonary fibrosis.

Key Facts

Frequently Asked Questions

How do I access dasatinib for longevity purposes?

Dasatinib is a prescription medication (Sprycel®, Bristol-Myers Squibb). In most countries, prescription requires physician evaluation. Longevity medicine practitioners, internists, and some gerontologists may prescribe it off-label for aging indications. Aging.ai and similar directories list longevity physicians.

What monitoring is required with D+Q?

CBC (platelet count monitoring for thrombocytopenia risk), liver function tests, and cardiac evaluation (ECG for QTc prolongation) are standard pre-treatment assessments. Repeat CBC after the first cycle is recommended.

Is D+Q safe for people without disease?

The safety profile of intermittent D+Q (2–3 days per quarter) in healthy aging individuals appears favorable, but no large safety trial has been conducted in this population specifically. The risk-benefit calculation favors caution without physician oversight.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.

Scientific References